Medtide

Medtide Financial Leverage

The Financial Leverage (Equity Multiplier) of Medtide (3880.HK) as of Oct 22, 2026 is 1.14. In the previous year, Financial Leverage (Equity Multiplier) was 3.68 — a change of -68.91% (lower).

Financial Leverage

1.14

YoY

-68.91%

Last updated:

Financial Leverage (Equity Multiplier) of Medtide is 2025 1.14 . Financial Leverage (Equity Multiplier) of Medtide was 2024 3.68 . It decreases by -68.91% lower compared to the previous year.

The Medtide Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2021
10.85 CNY
Jan 1, 2022
6.12 CNY
Jan 1, 2023
5.15 CNY
Jan 1, 2024
3.68 CNY
Jan 1, 2025
1.14 CNY
The Medtide Financial Leverage history
YEARFinancial LeverageYoY
1.14-68.91%
3.68-28.63%
5.15-15.77%
6.12-43.58%
10.85—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medtide Stock analysis

What does Medtide do? Medtide, Inc. generates revenue through peptide-focused contract research, development, and manufacturing services. The company offers CRO services for peptide new chemical entity (NCE) discovery and synthesis, alongside CDMO services covering peptide chemistry, manufacturing, and control (CMC) development and commercial production. Its primary clients are pharmaceutical companies seeking active pharmaceutical ingredients (APIs) rather than finished drug products, with services delivered across domestic and overseas markets. The firm's revenue streams are derived from these specialized peptide-related R&D and manufacturing contracts. Medtide's business model centers on providing comprehensive peptide development and manufacturing solutions, including CMC filing support for clients. The company's services target the API segment of the pharmaceutical industry, focusing on peptide-based drug development rather than final drug formulations. This specialization allows Medtide to serve clients requiring high-quality peptide synthesis and manufacturing capabilities for their drug development pipelines. The company's revenue is generated through direct contracts with pharmaceutical firms for peptide-related services, including discovery synthesis, CMC development, and commercial manufacturing. These services are delivered to clients operating in both domestic and international markets, with the firm emphasizing its expertise in peptide chemistry and manufacturing processes. Medtide's business model relies on its ability to provide end-to-end peptide development and manufacturing solutions to pharmaceutical clients. Medtide is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medtide stock

Financial Leverage (Equity Multiplier) of Medtide is 1.14 in 2025.

Financial Leverage (Equity Multiplier) of Medtide changed from 3.68 to 1.14, representing a -68.91% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) Medtide since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s Medtide with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Medtide

All Key Metrics — Medtide